MT-ND2 Antibody

What is MT-ND2 and what role does it play in mitochondrial function?

MT-ND2 (Mitochondrially Encoded NADH Dehydrogenase 2) is a core subunit of mitochondrial respiratory chain Complex I that plays a critical role in electron transfer from NADH to the respiratory chain. As a fundamental component of the minimal assembly required for catalysis, MT-ND2 facilitates electron transfer to ubiquinone, which functions as the immediate electron acceptor for the enzyme . This protein is encoded by mitochondrial DNA and functions as an essential component of oxidative phosphorylation. Research has shown that MT-ND2 is implicated in several pathologies including Leber hereditary optic neuropathy, multiple sclerosis, myocardial infarction, neurodegenerative diseases, and urinary bladder cancer . Additionally, certain mutations of MT-ND2, particularly the m.5178C>A mutation, have demonstrated protective effects against various diseases .

What are the standard applications for MT-ND2 antibodies in research protocols?

MT-ND2 antibodies are utilized across multiple experimental platforms with validated applications including:

For optimal results, researchers should conduct preliminary titration experiments on their specific samples, as antibody performance may vary between tissue types and experimental conditions .

How does antibody selection affect detection of MT-ND2 mutations or variants?

When studying MT-ND2 mutations like the m.5178C>A variant (which causes leucine-to-methionine substitution), antibody epitope location becomes critical. Most commercial antibodies target conserved regions of MT-ND2 and may not distinguish between wild-type and mutant forms . For mutation-specific detection:

• Select antibodies raised against peptides containing your region of interest

• Utilize paired antibody approaches (one targeting the conserved region, another targeting the mutation site)

• Consider complementary techniques such as genetic sequencing to confirm mutation status

For the m.5178C>A mutation specifically, researchers have established cell lines from individuals carrying this mutation to study its functional effects on mitochondrial activity rather than relying solely on antibody-based detection of the variant protein .

What are the critical validation steps for MT-ND2 antibody specificity?

Proper validation of MT-ND2 antibodies is essential as mitochondrial proteins can present cross-reactivity challenges. A comprehensive validation approach should include:

• Genetic controls: Testing in MT-ND2 knockdown/knockout models or cells depleted of mtDNA (as performed in study where "MT-ND2 was detected in human neonatal dermal fibroblasts and compared with mitochondria from fibroblasts depleted of mtDNA")

• Multiple antibody comparison: Using antibodies targeting different epitopes of MT-ND2 to confirm consistent localization and detection patterns

• Cross-species reactivity assessment: Verifying specificity across human, mouse, and rat samples if working with multiple models

• Technical controls: Including appropriate negative controls (secondary antibody only) and positive controls (tissues with known high MT-ND2 expression such as brain tissue)

• Band size verification: Confirming detection at the expected molecular weight (typically 39-44 kDa depending on the antibody)

What factors influence MT-ND2 protein detection in Western blotting?

MT-ND2 Western blotting requires optimization of several critical parameters:

• Sample preparation: Mitochondrial enrichment significantly improves detection. Standard protocols recommend:

  • Tissue homogenization in mitochondrial isolation buffer

  • Differential centrifugation (600-800g to remove nuclei, followed by 7,000-12,000g to pellet mitochondria)

  • Resuspension in appropriate lysis buffer with protease inhibitors

• Protein loading: 25-30 μg of total protein per lane is typically sufficient for detection in mitochondria-rich samples

• Gel percentage: 12-15% SDS-PAGE gels provide optimal resolution for the 39-44 kDa MT-ND2 protein

• Transfer conditions: Wet transfer at 30V overnight at 4°C improves transfer efficiency of hydrophobic mitochondrial membrane proteins

• Blocking conditions: 3-5% nonfat dry milk in TBST is effective for reducing background

• Antibody concentration: Titration between 1:500-1:2000 dilution depending on the specific antibody and sample type

• Detection method: Enhanced chemiluminescence (ECL) systems with 60-90 second exposure times typically provide clear signals

How should immunohistochemical detection of MT-ND2 be optimized?

For successful MT-ND2 immunohistochemistry:

• Fixation method: 10% neutral buffered formalin fixation for 24-48 hours is generally suitable

• Antigen retrieval:

  • Heat-induced epitope retrieval using TE buffer at pH 9.0 is recommended

  • Alternative approach: citrate buffer at pH 6.0 with high-pressure antigen retrieval

• Blocking parameters:

  • 3-5% BSA or serum from the species of secondary antibody origin

  • 30-60 minute incubation at room temperature

• Antibody dilution: Start with 1:50-1:200 dilution range and optimize based on signal-to-noise ratio

• Counterstaining: DAPI for nuclear visualization provides good contrast against mitochondrial staining

• Controls:

  • Positive control: human stomach tissue or colon carcinoma

  • Negative control: antibody diluent only

How should researchers address discrepancies in observed MT-ND2 molecular weight?

Commercial antibodies report MT-ND2 detection between 39-44 kDa , which can cause confusion when different products yield varying band patterns. These discrepancies may result from:

• Post-translational modifications: MT-ND2 can undergo various modifications affecting migration

• Protein complex association: Incomplete dissociation from Complex I can result in higher molecular weight bands

• Antibody specificity to different isoforms: Some antibodies may detect specific variants or processed forms

• Species differences: Human MT-ND2 may migrate differently than mouse or rat homologs

To address discrepancies:

• Run appropriate positive controls alongside your samples

• Consider multiple antibodies targeting different epitopes

• Document the exact molecular weight observed in your experimental system

• Validate critical findings with complementary approaches (e.g., mass spectrometry)

What causes variability in MT-ND2 immunofluorescence patterns?

Researchers may observe different MT-ND2 staining patterns depending on:

• Mitochondrial dynamics: Fragmentation or fusion states affecting distribution patterns

• Cell type variation: Different cell types exhibit distinct mitochondrial networks (e.g., neurons vs. fibroblasts)

• Fixation artifacts: Overfixation can mask epitopes while underfixation may preserve insufficient structure

• Antibody penetration issues: Permeabilization optimization is critical for accessing mitochondrial membrane proteins

To standardize immunofluorescence results:

• Use consistent fixation protocols (typically 4% paraformaldehyde for 10-15 minutes)

• Optimize permeabilization conditions (0.1-0.5% Triton X-100 for 5-10 minutes)

• Include mitochondrial counterstaining (e.g., MitoTracker dyes or other mitochondrial markers)

• Implement z-stack imaging to capture the full mitochondrial network

How can MT-ND2 antibodies be employed to study the protective effects of the m.5178C>A mutation?

The MT-ND2 m.5178C>A mutation demonstrates protective effects against several pathologies including myocardial infarction, cerebrovascular disease, type 2 diabetes, and atherosclerosis . To investigate these protective mechanisms:

• Comparative cell line studies: Establish lymphocyte lines from individuals with and without the mutation (as in study )

• Functional mitochondrial assays:

  • Measure oxygen consumption rate (OCR) parameters including basal OCR, ATP-linked OCR, maximal OCR, proton leak OCR, and reserve OCR

  • Assess mitochondrial membrane potential using fluorescent probes

  • Quantify ATP synthesis rates

  • Measure reactive oxygen species (ROS) production

• Cell viability and proliferation assessment:

  • Compare proliferation rates between wild-type and mutant cell lines

  • Evaluate apoptotic markers (Bcl-2 expression, Caspase 3/7 activity)

• Complex I activity assays:

  • Direct measurement of NADH dehydrogenase activity

  • Blue native PAGE analysis of intact respiratory complexes

Research has demonstrated that cells carrying the MT-ND2 m.5178C>A mutation exhibit increased ATP synthesis, decreased ROS production, increased mitochondrial membrane potential and Bcl-2 gene transcription/translation, and decreased early and late apoptosis compared to control cells .

What approaches are effective for studying MT-ND2's interaction with other mitochondrial proteins?

To investigate MT-ND2's protein-protein interactions:

• Co-immunoprecipitation:

  • Use MT-ND2 antibodies as bait to pull down interacting partners

  • Reverse approach: use antibodies against suspected interacting proteins to co-precipitate MT-ND2

  • Western blot or mass spectrometry to identify interacting proteins

• Proximity labeling approaches:

  • BioID or APEX2 fusion constructs for proximity-dependent biotinylation

  • Allows identification of transient interactions within the mitochondrial membrane environment

• Blue native PAGE:

  • Preserves native protein complexes

  • Western blot with MT-ND2 antibodies to identify complex formation

• Super-resolution microscopy:

  • Dual-color immunofluorescence with MT-ND2 and other potential interacting proteins

  • STORM or PALM imaging to resolve nanoscale proximity

• Crosslinking mass spectrometry:

  • Chemical crosslinking of proximal proteins followed by mass spectrometry

  • Provides information on spatial relationships between MT-ND2 and other proteins

How can researchers differentiate between MT-ND2 and nuclear-encoded Complex I subunits with similar properties?

Distinguishing MT-ND2 from other Complex I subunits requires careful experimental design:

• Genetic approaches:

  • mtDNA depletion models affect only mitochondrially-encoded subunits

  • Selective knockdown of nuclear-encoded subunits

• Antibody selection criteria:

  • Verify antibody epitope has no homology with other Complex I subunits

  • Validate using knockout/knockdown controls

• Mitochondrial isolation quality:

  • Density gradient purification to remove contaminating membranes

  • Verification of mitochondrial purity using markers for other cellular compartments

• Mass spectrometry identification:

  • Peptide mapping to differentiate between similar proteins

  • Label-free quantification to determine relative abundance

• Genomic origin verification:

  • Selective inhibition of mitochondrial vs. nuclear translation (chloramphenicol vs. cycloheximide)

  • Pulse-chase labeling to distinguish newly synthesized proteins

How are MT-ND2 antibodies being utilized in research on neurodegenerative diseases?

MT-ND2 has been implicated in several neurodegenerative conditions, including potential associations with Alzheimer's disease . Current research approaches include:

• Post-mortem tissue analysis:

  • Comparative immunohistochemistry of affected vs. unaffected brain regions

  • Quantification of MT-ND2 levels in different stages of disease progression

• Patient-derived models:

  • iPSC-derived neurons from patients with MT-ND2 mutations

  • Organoid models to study MT-ND2 function in 3D neural tissues

• Mitochondrial dynamics assessment:

  • Live-cell imaging of mitochondrial morphology and transport in neurons

  • Correlation between MT-ND2 variants and mitochondrial fragmentation

• Biomarker development:

  • Analysis of circulating cell-free mtDNA containing MT-ND2 mutations

  • Correlation with disease progression and therapeutic response

Research demonstrates that protective MT-ND2 variants may influence disease susceptibility through modulation of oxidative stress, mitochondrial membrane potential, and apoptotic pathways .

What novel techniques are emerging for studying MT-ND2 transcription factor binding and regulation?

Recent research has revealed that nuclear transcription factors can bind to mitochondrial DNA and potentially regulate MT-ND2 expression:

• ChIP-seq applications:

  • Studies have identified several transcription factors (including ATF2, ATF3, CEBPB) with potential binding sites near MT-ND2 and other mitochondrial genes

  • Peaks observed over mitochondrial genes MT-ND3, MT-ND4L, MT-ATP6, and MT-CYB suggest potential regulatory regions

• BPNet predictive modeling:

  • Computational approaches to predict transcription factor binding profiles on mitochondrial DNA

  • Integration of experimental data with predictive models to identify regulatory elements

• Validation approaches:

  • Multiple antibody verification (different epitopes, tagged proteins)

  • Cross-cell line confirmation to identify consistent binding patterns

  • Functional validation using reporter constructs

• Advanced microscopy:

  • Immuno-gold labeling with electron microscopy to directly visualize transcription factor localization to mitochondria

  • Super-resolution approaches to study co-localization patterns